DuraCAR / Regen BioPharma - LARVOL DELTA

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024 (PRNewswire) - "Regen BioPharma, Inc...will be presenting at the Emerging Growth Conference on January 10, 2024....'We plan to use this time to update our shareholders on our fiscal and scientific goals for the upcoming year, discuss our progress on current programs and timeline regarding our DuraCAR program.'"

Preclinical • Oncology • Solid Tumor

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023 (PRNewswire) - "Regen BioPharma, Inc...will be presenting at the Emerging Growth Conference on December 7, 2023....'We plan to use this time to discuss our progress and timeline regarding our DuraCAR program as well as update our shareholders on our financial plan.'"

Preclinical • Oncology • Solid Tumor

Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments (PRNewswire) - "Regen BioPharma, Inc...The Company has announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of the Company's DuraCAR cells...The Company is preparing a series of in vitro studies to test its DuraCAR cells in both immunosuppressive and in tumor-killing experiments. The experiments to explore whether these cells have an immunosuppressive effect include mixing the DuraCAR cells with activated immune cells that are designed to kill target tumor cells and to determine if these cells suppress this killing. In addition, the same experiments will be able to determine if the DuraCAR cells have a direct effect on killing tumors cells."

Commercial • Preclinical • Oncology • Solid Tumor

Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program (PRNewswire) - "The Company has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression."

Preclinical • Oncology • Solid Tumor

Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023 (PRNewswire) - "Regen BioPharma, Inc...will be presenting at the Emerging Growth Conference on November 1, 2023...'We plan to use this time to discuss our most recent scientific results around our DuraCAR program as well as update our shareholders on our financial plan.'"

Preclinical • Oncology

Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies (PRNewswire) - "The first phase of in vitro experiments successfully synthesized and expressed in transfected cells the chimeric antigen receptor (CAR) construct targeting CD19 and NR2F6. However, a second set of experiments yielded unexpected results whereby siRNAs designed to suppress NR2F6 mRNA expression yielded the opposite result. The company has engaged a contract research organization (CRO) that is independent of the CRO which performed the second set of experiments to determine if these surprising findings are reproducible. If confirmed, these results could lead to the development of a therapy whereby T-Cells that suppress autoimmunity can be created."

Licensing / partnership • Preclinical • Oncology • Solid Tumor